keyword
MENU ▼
Read by QxMD icon Read
search

Immunomodulation

keyword
https://www.readbyqxmd.com/read/28551874/coptidis-rhizoma-extract-inhibits-replication-of-respiratory-syncytial-virus-in-vitro-and-in-vivo-by-inducing-antiviral-state
#1
Byeong-Hoon Lee, Kiramage Chathuranga, Md Bashir Uddin, Prasanna Weeratunga, Myun Soo Kim, Won-Kyung Cho, Hong Ik Kim, Jin Yeul Ma, Jong-Soo Lee
Coptidis Rhizoma is derived from the dried rhizome of Ranunculaceous plants and is a commonly used traditional Chinese medicine. Although Coptidis Rhizoma is commonly used for its many therapeutic effects, antiviral activity against respiratory syncytial virus (RSV) has not been reported in detail. In this study, we evaluated the antiviral activities of Coptidis Rhizoma extract (CRE) against RSV in human respiratory tract cell line (HEp2) and BALB/c mice. An effective dose of CRE significantly reduces the replication of RSV in HEp2 cells and reduces the RSV-induced cell death...
June 2017: Journal of Microbiology / the Microbiological Society of Korea
https://www.readbyqxmd.com/read/28551208/dualistic-immunomodulation-of-sub-chronic-microcystin-lr-exposure-on-the-innate-immune-defense-system-in-male-zebrafish
#2
Wang Lin, Jie Hou, Honghui Guo, Yuming Qiu, Li Li, Dapeng Li, Rong Tang
Microcystins (MCs), produced by toxic cyanobacterial blooms that appeared world wildly in eutrophication waters, have often caused fish illness and even massive death cases. Among at least 90 structural variants, microcystin-LR (MC-LR) is the most common and toxic variant. In order to better understand innate immune responses in fish disrupted by environmental concentrations of MC-LR, male zebrafish (Danio rerio) were exposed to 0, 0.3, 1, 3, 10 and 30 μg/L MC-LR for 30 d, and the changes in splenic pathology and immunological gene expression as well as serum immune parameters were studied...
May 16, 2017: Chemosphere
https://www.readbyqxmd.com/read/28548608/a-descriptive-review-of-additional-risk-minimisation-measures-applied-to-eu-centrally-authorised-medicines-2006-2015
#3
Annalisa Rubino, Esther Artime
BACKGROUND: Guidance on therapeutic risk management, first released in EU in 2005, was updated in 2012-2013 with increased requirements on additional risk minimisation measures (aRMM). This study describes aRMM imposed at initial EU central marketing authorisation of medicines in 2006-2015. METHODS: Non-generic medicines authorised between 01/01/2006 and 31/12/2015 were identified in the European Public Assessment Report (EPAR) database. Data on aRMM, including effectiveness measures were extracted, tabulated and analysed with Excel 2016 for chi-square p value estimates and linear regression modelling as appropriate...
May 26, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28546082/targeting-gpnmb-with-glembatumumab-vedotin-current-developments-and-future-opportunities-for-the-treatment-of-cancer
#4
REVIEW
April A N Rose, Marco Biondini, Rafael Curiel, Peter M Siegel
GPNMB has emerged as an immunomodulator and an important positive mediator of tumor progression and metastasis in numerous solid cancers. Tumor intrinsic GPNMB-mediated effects on cellular signaling, coupled with the ability of GPNMB to influence the primary tumor and metastatic microenvironments in a non-cell autonomous fashion, combine to augment malignant cancer phenotypes. In addition, GPNMB is often overexpressed in a variety of cancers, making it an attractive therapeutic target. In this regard, glembatumumab vedotin, an antibody-drug conjugate (ADC) that targets GPNMB, is currently in clinical trials as a single agent in multiple cancers...
May 22, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28545927/stem-cells-to-restore-insulin-production-and-cure-diabetes
#5
V Sordi, S Pellegrini, M Krampera, P Marchetti, A Pessina, G Ciardelli, G Fadini, C Pintus, G Pantè, L Piemonti
BACKGROUND: The advancement of knowledge in the field of regenerative medicine is increasing the therapeutic expectations of patients and clinicians on cell therapy approaches. Within these, stem cell therapies are often evoked as a possible therapeutic option for diabetes, already ongoing or possible in the near future. AIM: The purpose of this document is to make a point of the situation on existing knowledge and therapies with stem cells to treat patients with diabetes by focusing on some of the aspects that most frequently raise curiosity and discussion in clinical practice and in the interaction with the patient...
February 21, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28542298/early-anti-tnf-immunomodulator-therapy-is-associated-with-better-long-term-clinical-outcomes-in-asian-patients-with-crohn-s-disease-with-poor-prognostic-factors
#6
Eun Hye Oh, Kyunghwan Oh, Minkyu Han, Hyungil Seo, Kiju Chang, Sun-Ho Lee, Gwang-Un Kim, Eun Mi Song, Myeongsook Seo, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Although early treatment of Crohn's disease (CD) patients with anti-tumor necrosis factor (TNF) agents or immunomodulators (IMs) may improve long-term outcomes, especially those with poor prognostic factors, their effectiveness in Asians remains unclear. In this study, Korean patients with CD naïve to both intestinal surgery and intestinal complications, and with at least two risk factors for progression (diagnosis at age <40 years, systemic corticosteroid treatment <3 months after diagnosis, and perianal fistula at diagnosis) were retrospectively analyzed...
2017: PloS One
https://www.readbyqxmd.com/read/28541437/hyperferritinemia-and-inflammation
#7
Kate Kernan, Joseph A Carcillo
Understanding of ferritin biology has traditionally centered on its role in iron storage and homeostasis, with low ferritin levels indicative of deficiency and high levels indicative of primary or secondary hemochromatosis. However, further work has shown that iron, redox biology and inflammation are inexorably linked. During infection, increased ferritin levels represent an important host defense mechanism that deprives bacterial growth of iron and protect immune cell function. It may also be protective, limiting the production of free radicals and mediating immunomodulation...
May 25, 2017: International Immunology
https://www.readbyqxmd.com/read/28539203/the-interplay-between-neuroendocrine-activity-and-psychological-stress-induced-exacerbation-of-allergic-asthma
#8
REVIEW
Tomomitsu Miyasaka, Kaori Dobashi-Okuyama, Tomoko Takahashi, Motoaki Takayanagi, Isao Ohno
Psychological stress is recognized as a key factor in the exacerbation of allergic asthma, whereby brain responses to stress act as immunomodulators for asthma. In particular, stress-induced enhanced type 2 T-helper (Th2)-type lung inflammation is strongly associated with asthma pathogenesis. Psychological stress leads to eosinophilic airway inflammation through activation of the hypothalamic-pituitary-adrenal pathway and autonomic nervous system. This is followed by the secretion of stress hormones into the blood, including glucocorticoids, epinephrine, and norepinephrine, which enhance Th2 and type 17 T-helper (Th17)-type asthma profiles in humans and rodents...
May 20, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/28538644/validation-of-a-clinical-trial-composite-endpoint-for-patients-with-necrotizing-soft-tissue-infections
#9
Eileen M Bulger, Addison May, Wayne Dankner, Greg Maislin, Bryce Robinson, Anat Shirvan
OBJECTIVE: Our objective was to develop and validate a composite endpoint for patients with necrotizing soft tissue infections (NSTI) that incorporates: local tissue injury, systemic organ dysfunction, and mortality. METHODS: The Necrotizing Infection Clinical Composite Endpoint (NICCE) was defined as follows:(i) Alive at day 28 (ii) ≤3 debridements prior to day 14 (iii) No amputation beyond first debridement (iv) Modified SOFA score (mSOFA) at day 14 ≤1. To be considered a success, all individual criteria must be met...
May 22, 2017: Journal of Trauma and Acute Care Surgery
https://www.readbyqxmd.com/read/28538510/thalidomide-induced-stroke-in-a-child-with-thalassemia-major
#10
Sushil Gunaseelan, Anand Prakash
β-thalassemia major is a hereditary anemia resulting from defects in β-globin production. It is also characterized by a hypercoagulable state with an increased risk of thrombosis. Thalidomide, a drug known for its immunomodulating and antiangiogenic properties, has recently been demonstrated to induce γ-globin gene expression and to increase the proliferation of erythroid cells. An increasing incidence of thromboembolic events in thalidomide-treated patients has been reported. This is often in the context of thalidomide combinations with other drugs, including steroids and particularly anthracycline-based chemotherapy, and with very low incidence of thrombosis with single-agent thalidomide treatment...
May 22, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28537880/biological-effects-and-epidemiological-consequences-of-arsenic-exposure-and-reagents-that-can-ameliorate-arsenic-damage-in-vivo
#11
REVIEW
Chinthalapally V Rao, Sanya Pal, Altaf Mohammed, Mudassir Farooqui, Mark P Doescher, Adam S Asch, Hiroshi Y Yamada
Through contaminated diet, water, and other forms of environmental exposure, arsenic affects human health. There are many U.S. and worldwide "hot spots" where the arsenic level in public water exceeds the maximum exposure limit. The biological effects of chronic arsenic exposure include generation of reactive oxygen species (ROS), leading to oxidative stress and DNA damage, epigenetic DNA modification, induction of genomic instability, and inflammation and immunomodulation, all of which can initiate carcinogenesis...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28536388/capitalizing-on-cancer-specific-replication-oncolytic-viruses-as-a-versatile-platform-for-the-enhancement-of-cancer-immunotherapy-strategies
#12
REVIEW
Donald Bastin, Scott R Walsh, Meena Al Saigh, Yonghong Wan
The past decade has seen considerable excitement in the use of biological therapies in treating neoplastic disease. In particular, cancer immunotherapy and oncolytic virotherapy have emerged as two frontrunners in this regard with the first FDA approvals for agents in both categories being obtained in the last 5 years. It is becoming increasingly apparent that these two approaches are not mutually exclusive and that much of the therapeutic benefit obtained from the use of oncolytic viruses (OVs) is in fact the result of their immunotherapeutic function...
August 24, 2016: Biomedicines
https://www.readbyqxmd.com/read/28536324/-human-mesenchymal-stromal-stem-cell-as-a-source-of-cell-therapy-and-a-pharmacological-target-for-disease-treatment
#13
Yasuo Miura
Human mesenchymal stromal/stem cells(MSCs)show a multiple biological characteristics including the immunomodulation, tissue regeneration and hematopoiesis-supportive capability. Cell therapy by the use of MSCs has been extensively explored for a variety of diseases. Several tissues/organs are clinically available for a source of MSCs, and isolated cells are culture-expanded and subsequently injected into patients systemically or locally. MSCs organize the tissue/organ environment they reside, and in bone/marrow, MSCs differentiate into osteoblasts(OBs)that contribute to bone remodeling...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28535423/chromatographic-separation-and-detection-methods-of-aloe-arborescens-miller-constituents-a-systematic-review
#14
REVIEW
Jilan A Nazeam, Haidy A Gad, Hala M El-Hefnawy, Abdel-Naser B Singab
Aloe arborescens Miller (Family Asphodelaceae) is a member of genus Aloe, which is used in traditional medicine to cure various diseases. The extracts of the plant have been reported to possess anticancer, immunomodulator, antidiabetic, anti-inflammatory and antioxidant activities. The phytochemical investigations have revealed diverse chemical constituents, including phenolics [anthraquinones, anthrones, pyrones, chromones and coumarins], polysaccharides [arborans [(1-4) linked glucomannans, polysaccharide (A, B and C): (A: a linear (1-6)-O-α-glucan, B: a branching (1-2)-O-l-arabinose with (1-2)-O-d-galactose linkages and C: (1-4)-O-β-mannan with 18% acetyl group)]], glycoproteins and carboxypeptidase enzyme...
April 29, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28534310/combination-immunotherapy-for-type-1-diabetes
#15
REVIEW
Robert N Bone, Carmella Evans-Molina
PURPOSE OF REVIEW: Type 1 diabetes (T1D) is an autoimmune disease marked by β-cell destruction. Immunotherapies for T1D have been investigated since the 1980s and have focused on restoration of tolerance, T cell or B cell inhibition, regulatory T cell (Treg) induction, suppression of innate immunity and inflammation, immune system reset, and islet transplantation. The purpose of this review is to provide an overview and lessons learned from single immunotherapy trials, describe recent and ongoing combination immunotherapy trials, and provide perspectives on strategies for future combination clinical interventions aimed at preserving insulin secretion in T1D...
July 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28533919/combination-therapy-for-inflammatory-bowel-disease
#16
REVIEW
Keith S Sultan, Joshua C Berkowitz, Sundas Khan
Biologic therapies such as infliximab and adalimumab have become mainstays of treatment for inflammatory bowel disease. Early studies suggested that combination therapy (CT) with infliximab and an immunomodulator drug such as azathioprine may help optimize biologic pharmacokinetics, minimize immunogenicity, and improve outcomes. The landmark SONIC trial in Crohn's disease and the UC SUCCESS trial in ulcerative colitis demonstrated CT with infliximab and azathioprine to be superior to monotherapy with either agent alone at inducing clinical remission in treatment naïve patients with moderate to severe disease...
May 6, 2017: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28532691/bio-synthetic-materials-for-immunomodulation-of-islet-transplants
#17
Greg A Foster, Andrés J García
Clinical islet transplantation is an effective therapy in restoring physiological glycemic control in type 1 diabetics. However, allogeneic islets derived from cadaveric sources elicit immune responses that result in acute and chronic islet destruction. To prevent immune destruction of islets, transplant recipients require lifelong delivery of immunosuppressive drugs, which are associated with debilitating side effects. Biomaterial-based strategies to eliminate the need for immunosuppressive drugs are an emerging therapy for improving islet transplantation...
May 19, 2017: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/28532690/combinatorial-drug-delivery-approaches-for-immunomodulation
#18
Joshua M Stewart, Benjamin G Keselowsky
Immunotherapy has been widely explored for applications to both augment or suppress intrinsic host immunity. Clinical achievements have seen a number of immunotherapeutic drugs displace established strategies like chemotherapy in treating immune-associated diseases. However, single drug approaches modulating an individual arm of the immune system are often incompletely effective. Imperfect mechanistic understanding and heterogeneity within disease pathology have seen monotherapies inadequately equipped to mediate complete disease remission...
May 19, 2017: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/28530053/-alopecia-areata
#19
REVIEW
Yaron Zafrir, Sharon Baum, Shoshi Greenberger, Anna Lyakhovitsky, Aviv Barzilai
Alopecia areata (AA) is an organ specific autoimmune disease. Similar to other autoimmune diseases, its pathogenesis is believed to be an interaction of genetic, environmental and immune factors. Studies have shown that autoreactive lymphocytes affect anagen hair follicles leading to subsequent shedding of hairs and alopecia. Clinically, the disease is characterized by sudden nonscarring hair loss that usually involves the scalp, but may also affect the face and other body areas, and indeed the entire body hair...
October 2016: Harefuah
https://www.readbyqxmd.com/read/28528528/ustekinumab-a-review-in-moderate-to-severe-crohn-s-disease
#20
Yvette N Lamb, Sean T Duggan
Ustekinumab (Stelara(®)) has been recently approved in the EU and the USA as intravenous induction and subcutaneous maintenance therapy for adult patients with moderately to severely active Crohn's disease who have failed or were intolerant to treatment with immunomodulators, corticosteroids or at least one tumour necrosis factor (TNF) antagonist. Ustekinumab, a monoclonal antibody to the shared p40 subunit of the proinflammatory interleukin (IL)-12 and IL-23 cytokines, has a unique mechanism of action distinct from that of TNF antagonists...
May 20, 2017: Drugs
keyword
keyword
63245
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"